Which has better earnings and valuation, CTSO or NRXS?

Cytosorbents has higher revenue and earnings than NeurAxis. NeurAxis is trading at a lower price-to-earnings ratio than Cytosorbents, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cytosorbents $37.06M 0.49 -$8.20M -$5.80 N/A NeurAxis $5.32M 17.98 -$14.63M -$0.78 N/A

Is CTSO or NRXS more profitable?

Cytosorbents has a net margin of -48.94% compared to NeurAxis' net margin of -492.76%. NeurAxis' return on equity of 0.00% beat Cytosorbents' return on equity. Company Net Margins Return on Equity Return on Assets Cytosorbents -48.94% -431.65% -41.94% NeurAxis -492.76% N/A -641.25%

Does the media prefer CTSO or NRXS?

In the previous week, NeurAxis had 1 more articles in the media than Cytosorbents. MarketBeat recorded 6 mentions for NeurAxis and 5 mentions for Cytosorbents. Cytosorbents' average media sentiment score of 0.69 beat NeurAxis' score of 0.64 indicating that Cytosorbents is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cytosorbents 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive NeurAxis 1 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer CTSO or HSAQ?

Cytosorbents presently has a consensus target price of $107.50, indicating a potential upside of 1,769.57%. Given Cytosorbents' stronger consensus rating and higher possible upside, equities analysts plainly believe Cytosorbents is more favorable than Health Sciences Acquisitions Co. 2. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cytosorbents 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Health Sciences Acquisitions Co. 2 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better valuation & earnings, CTSO or HSAQ?

Health Sciences Acquisitions Co. 2 has lower revenue, but higher earnings than Cytosorbents. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cytosorbents $37.06M 0.49 -$8.20M -$5.80 N/A Health Sciences Acquisitions Co. 2 N/A N/A -$380K N/A N/A

Do analysts recommend CTSO or DXR?

Cytosorbents presently has a consensus price target of $107.50, indicating a potential upside of 1,769.57%. Given Cytosorbents' higher possible upside, research analysts clearly believe Cytosorbents is more favorable than Daxor. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cytosorbents 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Daxor 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50

Which has stronger earnings & valuation, CTSO or DXR?

Daxor has lower revenue, but higher earnings than Cytosorbents. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cytosorbents $37.06M 0.49 -$8.20M -$5.80 N/A Daxor N/A N/A N/A N/A N/A

Is CTSO or DXR more profitable?

Daxor has a net margin of 0.00% compared to Cytosorbents' net margin of -48.94%. Daxor's return on equity of 0.00% beat Cytosorbents' return on equity. Company Net Margins Return on Equity Return on Assets Cytosorbents -48.94% -431.65% -41.94% Daxor N/A N/A N/A

Does the media favor CTSO or DXR?

In the previous week, Cytosorbents had 3 more articles in the media than Daxor. MarketBeat recorded 5 mentions for Cytosorbents and 2 mentions for Daxor. Daxor's average media sentiment score of 0.97 beat Cytosorbents' score of 0.69 indicating that Daxor is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cytosorbents 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Daxor 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, NYXH or CTSO?

Cytosorbents has higher revenue and earnings than Nyxoah. Cytosorbents is trading at a lower price-to-earnings ratio than Nyxoah, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nyxoah $11.33M 5.06 -$101.92M -$2.52 N/A Cytosorbents $37.06M 0.49 -$8.20M -$5.80 N/A

Is NYXH or CTSO more profitable?

Cytosorbents has a net margin of -48.94% compared to Nyxoah's net margin of -443.16%. Nyxoah's return on equity of -178.90% beat Cytosorbents' return on equity. Company Net Margins Return on Equity Return on Assets Nyxoah -443.16% -178.90% -81.83% Cytosorbents -48.94% -431.65% -41.94%

Does the media refer more to NYXH or CTSO?

In the previous week, Cytosorbents had 3 more articles in the media than Nyxoah. MarketBeat recorded 5 mentions for Cytosorbents and 2 mentions for Nyxoah. Nyxoah's average media sentiment score of 0.96 beat Cytosorbents' score of 0.69 indicating that Nyxoah is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nyxoah 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cytosorbents 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Cytosorbents (CTSO) Competitors

$5.75 -0.01 (-0.17%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$5.74 -0.01 (-0.10%)

As of 09/18/2026 07:30 PM Eastern

Compare

CTSO vs. NRXS, HSAQ, DXR, NYXH, and OM

Should you buy Cytosorbents stock or one of its competitors? Cytosorbents's main competitors and comparable companies include NeurAxis (NRXS), Health Sciences Acquisitions Co. 2 (HSAQ), Daxor (DXR), Nyxoah (NYXH), and Outset Medical (OM). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Cytosorbents compare to NeurAxis?

Cytosorbents (NASDAQ:CTSO) and NeurAxis (NASDAQ:NRXS) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, earnings, media sentiment, institutional ownership, analyst recommendations, profitability, dividends and risk.

Cytosorbents has a net margin of -48.94% compared to NeurAxis' net margin of -492.76%. NeurAxis' return on equity of 0.00% beat Cytosorbents' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cytosorbents	-48.94%	-431.65%	-41.94%
NeurAxis	-492.76%	N/A	-641.25%

Cytosorbents has higher revenue and earnings than NeurAxis. NeurAxis is trading at a lower price-to-earnings ratio than Cytosorbents, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytosorbents	$37.06M	0.49	-$8.20M	-$5.80	N/A
NeurAxis	$5.32M	17.98	-$14.63M	-$0.78	N/A

32.9% of Cytosorbents shares are held by institutional investors. Comparatively, 11.8% of NeurAxis shares are held by institutional investors. 7.8% of Cytosorbents shares are held by company insiders. Comparatively, 21.1% of NeurAxis shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Cytosorbents presently has a consensus target price of $107.50, indicating a potential upside of 1,769.57%. NeurAxis has a consensus target price of $13.00, indicating a potential upside of 70.83%. Given Cytosorbents' higher possible upside, equities research analysts clearly believe Cytosorbents is more favorable than NeurAxis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytosorbents	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
NeurAxis	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Cytosorbents has a beta of 1.34, indicating that its stock price is 34% more volatile than the broader market. Comparatively, NeurAxis has a beta of 1.47, indicating that its stock price is 47% more volatile than the broader market.

In the previous week, NeurAxis had 1 more articles in the media than Cytosorbents. MarketBeat recorded 6 mentions for NeurAxis and 5 mentions for Cytosorbents. Cytosorbents' average media sentiment score of 0.69 beat NeurAxis' score of 0.64 indicating that Cytosorbents is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cytosorbents	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
NeurAxis	1 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Cytosorbents beats NeurAxis on 8 of the 15 factors compared between the two stocks.

How does Cytosorbents compare to Health Sciences Acquisitions Co. 2?

Cytosorbents (NASDAQ:CTSO) and Health Sciences Acquisitions Co. 2 (NASDAQ:HSAQ) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, profitability, valuation, analyst recommendations, institutional ownership and media sentiment.

32.9% of Cytosorbents shares are owned by institutional investors. Comparatively, 89.7% of Health Sciences Acquisitions Co. 2 shares are owned by institutional investors. 7.8% of Cytosorbents shares are owned by insiders. Comparatively, 21.9% of Health Sciences Acquisitions Co. 2 shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Health Sciences Acquisitions Co. 2 has a net margin of 0.00% compared to Cytosorbents' net margin of -48.94%. Health Sciences Acquisitions Co. 2's return on equity of 0.00% beat Cytosorbents' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cytosorbents	-48.94%	-431.65%	-41.94%
Health Sciences Acquisitions Co. 2	N/A	N/A	-2.38%

Health Sciences Acquisitions Co. 2 has lower revenue, but higher earnings than Cytosorbents.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytosorbents	$37.06M	0.49	-$8.20M	-$5.80	N/A
Health Sciences Acquisitions Co. 2	N/A	N/A	-$380K	N/A	N/A

In the previous week, Cytosorbents had 5 more articles in the media than Health Sciences Acquisitions Co. 2. MarketBeat recorded 5 mentions for Cytosorbents and 0 mentions for Health Sciences Acquisitions Co. 2. Cytosorbents' average media sentiment score of 0.69 beat Health Sciences Acquisitions Co. 2's score of 0.00 indicating that Cytosorbents is being referred to more favorably in the media.

Company	Overall Sentiment
Cytosorbents	Positive
Health Sciences Acquisitions Co. 2	Neutral

Cytosorbents has a beta of 1.34, indicating that its share price is 34% more volatile than the broader market. Comparatively, Health Sciences Acquisitions Co. 2 has a beta of 0.09, indicating that its share price is 91% less volatile than the broader market.

Cytosorbents presently has a consensus target price of $107.50, indicating a potential upside of 1,769.57%. Given Cytosorbents' stronger consensus rating and higher possible upside, equities analysts plainly believe Cytosorbents is more favorable than Health Sciences Acquisitions Co. 2.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytosorbents	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Health Sciences Acquisitions Co. 2	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Cytosorbents beats Health Sciences Acquisitions Co. 2 on 7 of the 13 factors compared between the two stocks.

How does Cytosorbents compare to Daxor?

Cytosorbents (NASDAQ:CTSO) and Daxor (NASDAQ:DXR) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their risk, profitability, dividends, media sentiment, institutional ownership, valuation, earnings and analyst recommendations.

Daxor has a net margin of 0.00% compared to Cytosorbents' net margin of -48.94%. Daxor's return on equity of 0.00% beat Cytosorbents' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cytosorbents	-48.94%	-431.65%	-41.94%
Daxor	N/A	N/A	N/A

Cytosorbents presently has a consensus price target of $107.50, indicating a potential upside of 1,769.57%. Given Cytosorbents' higher possible upside, research analysts clearly believe Cytosorbents is more favorable than Daxor.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytosorbents	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Daxor	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Cytosorbents had 3 more articles in the media than Daxor. MarketBeat recorded 5 mentions for Cytosorbents and 2 mentions for Daxor. Daxor's average media sentiment score of 0.97 beat Cytosorbents' score of 0.69 indicating that Daxor is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cytosorbents	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Daxor	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Daxor has lower revenue, but higher earnings than Cytosorbents.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytosorbents	$37.06M	0.49	-$8.20M	-$5.80	N/A
Daxor	N/A	N/A	N/A	N/A	N/A

Cytosorbents has a beta of 1.34, suggesting that its share price is 34% more volatile than the broader market. Comparatively, Daxor has a beta of 0.26, suggesting that its share price is 74% less volatile than the broader market.

32.9% of Cytosorbents shares are owned by institutional investors. Comparatively, 1.3% of Daxor shares are owned by institutional investors. 7.8% of Cytosorbents shares are owned by company insiders. Comparatively, 51.5% of Daxor shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Daxor beats Cytosorbents on 6 of the 11 factors compared between the two stocks.

How does Cytosorbents compare to Nyxoah?

Nyxoah (NASDAQ:NYXH) and Cytosorbents (NASDAQ:CTSO) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, profitability, earnings, valuation, institutional ownership, analyst recommendations and media sentiment.

In the previous week, Cytosorbents had 3 more articles in the media than Nyxoah. MarketBeat recorded 5 mentions for Cytosorbents and 2 mentions for Nyxoah. Nyxoah's average media sentiment score of 0.96 beat Cytosorbents' score of 0.69 indicating that Nyxoah is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nyxoah	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cytosorbents	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Nyxoah currently has a consensus price target of $4.26, indicating a potential upside of 187.97%. Cytosorbents has a consensus price target of $107.50, indicating a potential upside of 1,769.57%. Given Cytosorbents' higher probable upside, analysts clearly believe Cytosorbents is more favorable than Nyxoah.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nyxoah	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Cytosorbents	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

32.9% of Cytosorbents shares are owned by institutional investors. 17.1% of Nyxoah shares are owned by insiders. Comparatively, 7.8% of Cytosorbents shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Cytosorbents has higher revenue and earnings than Nyxoah. Cytosorbents is trading at a lower price-to-earnings ratio than Nyxoah, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nyxoah	$11.33M	5.06	-$101.92M	-$2.52	N/A
Cytosorbents	$37.06M	0.49	-$8.20M	-$5.80	N/A

Nyxoah has a beta of 1.63, indicating that its stock price is 63% more volatile than the broader market. Comparatively, Cytosorbents has a beta of 1.34, indicating that its stock price is 34% more volatile than the broader market.

Cytosorbents has a net margin of -48.94% compared to Nyxoah's net margin of -443.16%. Nyxoah's return on equity of -178.90% beat Cytosorbents' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nyxoah	-443.16%	-178.90%	-81.83%
Cytosorbents	-48.94%	-431.65%	-41.94%

Summary

Nyxoah beats Cytosorbents on 9 of the 16 factors compared between the two stocks.

How does Cytosorbents compare to Outset Medical?

Cytosorbents (NASDAQ:CTSO) and Outset Medical (NASDAQ:OM) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, valuation, media sentiment, analyst recommendations, institutional ownership and dividends.

Cytosorbents has a net margin of -48.94% compared to Outset Medical's net margin of -63.06%. Outset Medical's return on equity of -61.67% beat Cytosorbents' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cytosorbents	-48.94%	-431.65%	-41.94%
Outset Medical	-63.06%	-61.67%	-28.25%

32.9% of Cytosorbents shares are owned by institutional investors. 7.8% of Cytosorbents shares are owned by insiders. Comparatively, 2.5% of Outset Medical shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Cytosorbents has a beta of 1.34, meaning that its share price is 34% more volatile than the broader market. Comparatively, Outset Medical has a beta of 1.9, meaning that its share price is 90% more volatile than the broader market.

In the previous week, Cytosorbents had 5 more articles in the media than Outset Medical. MarketBeat recorded 5 mentions for Cytosorbents and 0 mentions for Outset Medical. Cytosorbents' average media sentiment score of 0.69 beat Outset Medical's score of 0.00 indicating that Cytosorbents is being referred to more favorably in the media.

Company	Overall Sentiment
Cytosorbents	Positive
Outset Medical	Neutral

Cytosorbents currently has a consensus target price of $107.50, indicating a potential upside of 1,769.57%. Outset Medical has a consensus target price of $10.00, indicating a potential upside of 217.46%. Given Cytosorbents' higher possible upside, research analysts plainly believe Cytosorbents is more favorable than Outset Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytosorbents	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Outset Medical	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Cytosorbents has higher earnings, but lower revenue than Outset Medical. Cytosorbents is trading at a lower price-to-earnings ratio than Outset Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytosorbents	$37.06M	0.49	-$8.20M	-$5.80	N/A
Outset Medical	$119.48M	0.50	-$81.65M	-$4.09	N/A

Summary

Outset Medical beats Cytosorbents on 9 of the 16 factors compared between the two stocks.

Get Cytosorbents News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CTSO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CTSO vs. The Competition

Export

Metric	Cytosorbents	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$18.12M	$5.55B	$7.24B	$13.19B
Dividend Yield	N/A	1.80%	2.57%	12.81%
P/E Ratio	-0.99	25.34	275.49	25.40
Price / Sales	0.49	72.49	646.01	89.45
Price / Cash	N/A	32.64	76.25	51.42
Price / Book	3.06	5.69	10.46	6.33
Net Income	-$8.20M	$151.55M	$3.49B	$358.33M
7 Day Performance	-10.30%	0.66%	0.59%	1.12%
1 Month Performance	-7.59%	-3.33%	-1.74%	-2.39%
1 Year Performance	-69.45%	6.79%	18.13%	5.35%

Cytosorbents Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CTSO Cytosorbents	2.3783 of 5 stars	$5.75 -0.2%	$107.50 +1,769.6%	-69.5%	$18.12M	$37.06M	N/A	129	Gap Up
NRXS NeurAxis	1.7822 of 5 stars	$5.70 -0.9%	$13.00 +128.1%	+199.6%	$71.58M	$5.32M	N/A	19
HSAQ Health Sciences Acquisitions Co. 2	N/A	$5.90 -3.6%	N/A	+142.2%	$66.15M	N/A	N/A	4
DXR Daxor	1.5246 of 5 stars	$11.15 -1.1%	N/A	-3.6%	$65.09M	$8.15M	N/A	37	Short Interest Increase
NYXH Nyxoah	3.4738 of 5 stars	$1.54 -3.8%	$4.26 +176.8%	-70.0%	$59.69M	$21.66M	N/A	110	Analyst Forecast Short Interest Decrease

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CTSO) was last updated on 9/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cytosorbents (CTSO) Competitors

CTSO vs. NRXS, HSAQ, DXR, NYXH, and OM

How does Cytosorbents compare to NeurAxis?

Summary

How does Cytosorbents compare to Health Sciences Acquisitions Co. 2?

Summary

How does Cytosorbents compare to Daxor?

Summary

How does Cytosorbents compare to Nyxoah?

Summary

How does Cytosorbents compare to Outset Medical?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTSO vs. The Competition

Cytosorbents Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cytosorbents (CTSO) Competitors

CTSO vs. NRXS, HSAQ, DXR, NYXH, and OM

How does Cytosorbents compare to NeurAxis?

Is CTSO or NRXS more profitable?

Which has better earnings and valuation, CTSO or NRXS?

Do institutionals and insiders believe in CTSO or NRXS?

Do analysts prefer CTSO or NRXS?

Which has more volatility and risk, CTSO or NRXS?

Does the media prefer CTSO or NRXS?

Summary

How does Cytosorbents compare to Health Sciences Acquisitions Co. 2?

Do institutionals and insiders believe in CTSO or HSAQ?

Is CTSO or HSAQ more profitable?

Which has better valuation & earnings, CTSO or HSAQ?

Does the media prefer CTSO or HSAQ?

Which has more risk and volatility, CTSO or HSAQ?

Do analysts prefer CTSO or HSAQ?

Summary

How does Cytosorbents compare to Daxor?

Is CTSO or DXR more profitable?

Do analysts recommend CTSO or DXR?

Does the media favor CTSO or DXR?

Which has stronger earnings & valuation, CTSO or DXR?

Which has more risk and volatility, CTSO or DXR?

Do insiders and institutionals believe in CTSO or DXR?

Summary

How does Cytosorbents compare to Nyxoah?

Does the media refer more to NYXH or CTSO?

Do analysts recommend NYXH or CTSO?

Do insiders and institutionals have more ownership in NYXH or CTSO?

Which has preferable valuation & earnings, NYXH or CTSO?

Which has more volatility and risk, NYXH or CTSO?

Is NYXH or CTSO more profitable?

Summary

How does Cytosorbents compare to Outset Medical?

Is CTSO or OM more profitable?

Do insiders & institutionals have more ownership in CTSO or OM?

Which has more volatility and risk, CTSO or OM?

Does the media refer more to CTSO or OM?

Do analysts rate CTSO or OM?

Which has preferable valuation and earnings, CTSO or OM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTSO vs. The Competition

Cytosorbents Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools